Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
9M 2018 Results presentation
Operating income, growth figures, profitability and how our products have behaved.
Tue, 06/11/2018 - 11:15
0 min
Español
0185(1).jpg
Download related document
Select rating
Give 9M 2018 Results presentation 1/5
Give 9M 2018 Results presentation 2/5
Give 9M 2018 Results presentation 3/5
Give 9M 2018 Results presentation 4/5
Give 9M 2018 Results presentation 5/5
No votes yet
Related
ROVI launches an initiative to develop solutions that improve sustained-release...
Sustained-release drug delivery is a field where significant progress is being made that increases the efficacy of the medicines, improves...
3 min
24/11/2022
2022 Capital Markets Day presentation
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION (COMISIÓN NACIONAL DEL MERCADO DE VALORES) Madrid, 23 November 2022 In...
1 min
23/11/2022
First nine months 2022 results press release
ROVI reports operating revenue growth of 24% and EBITDA growth of 25% • Operating revenue increased by 24% to 575.5 million euros driven...
3 min
04/11/2022
See More
Email
Facebook
Twitter
LinkedIn
0185(1).jpg